Dermatology category leader

In March 2024, Galderma Group AG (“Galderma”) became a publicly listed company on the SIX Swiss Exchange, marking the next step of Galderma’s growth trajectory as the pure-play dermatology category leader.

Galderma’s first phase of growth, from becoming an independent company in 2019 to 2023, was focused on establishing an integrated dermatology platform to rapidly unlock strong growth momentum. Its next phase of growth from 2024 onwards will focus on executing an already proven strategy, to continue outgrowing the market with further incremental growth from differentiated biologic launches and to deliver attractive margin expansion in the medium term.

With its establishment in 1981 as a joint venture between L’Oréal and Nestlé following the invention of the first Cetaphil formulation over 75 years ago, Galderma has developed a strong consumer heritage and deep science foundation in dermatology. Through its 40-year history in dermatology, Galderma has dedicated its focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals.

Galderma has since built a ‘self-care’ leadership profile fully dedicated to dermatology, which is the fastest-growing ‘self-care’ market, by scaling blockbuster platforms in neuromodulators as well as fillers and biostimulators within Injectable Aesthetics, in Dermatological Skincare, and in Therapeutic Dermatology. These are the most attractive segments of the dermatology market, with strong growth fundamentals, in which Galderma has a financial track record of delivering consistent and highly profitable above-market growth.

Deploying a proven integrated dermatology strategy tailored to consumer-driven purchasing decisions and the pivotal role of healthcare professionals, Galderma has a global integrated platform with presence in over 90 countries which is optimized for commercial synergies and platform efficiencies. Galderma benefits from competitive advantages and premium positioning by focusing on three strategic pillars leveraging: (1) the broadest portfolio with leading science and innovation; (2) global scale with omni-channel execution excellence; and (3) market-leading education and services.

Galderma is a consumer-centric business, with more than 90% of net sales being paid by consumers ‘out-of-pocket’, with digitally-enabled execution and trusted partnerships with healthcare professionals. Focused on achieving superior, science-based outcomes for patients and consumers, Galderma is advancing dermatology for every skin story. Also convinced that the health of everyone’s skin is a reflection of the world we live in, Galderma’s commitment to social and environmental sustainability is integral to the way the company operates.

Galderma made the strategic decision to conduct an Initial Public Offering in March 2024 to broaden its shareholder base and transition the capital structure in support of its growth strategy and ambition. Galderma used the proceeds to strengthen its balance sheet by repaying debt and to further accelerate its organic growth momentum fueled by its unique integrated dermatology strategy.